{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-085653","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.751171+00:00","generated_at":"2026-05-31T17:56:28.133514+00:00","sec_items":["1.01","2.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"KalVista Pharmaceuticals enters lease for HQ and lab in Framingham; aggregate rent ~$11.2M","bullets":["Lease for 32,110 sq ft at 200 Crossing Blvd, Framingham, MA, as corporate HQ and lab space.","Commencement on or about April 30, 2025; lease expires December 31, 2034.","Aggregate base rent payments of approximately $11.2 million over the term.","Security deposit of ~$652,800 in the form of a letter of credit.","Company to pay pro rata share of operating expenses and certain taxes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-085653","json":"https://secwatch.observer/filing/0000950170-24-085653.json","markdown":"https://secwatch.observer/filing/0000950170-24-085653.md","text":"https://secwatch.observer/filing/0000950170-24-085653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024085653/0000950170-24-085653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024085653/kalv-20240722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T17:56:28.133514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}